Suscribirse a:
Enviar comentarios (Atom)
Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
Adding GLPG2737, Galapagos’ investigational CFTR corrector, to Vertex’s Orkambi (lumacaftor/ivacaftor) enhances the effectiveness of the treatment in cystic fibrosis patients with two copies of the F508del mutation, topline results from a Phase 2 trial show. Conducted at multiple sites in Germany, the Phase 2 PELICAN clinical trial (NCT03474042) evaluated the effectiveness, safety, and tolerability of the […] The post GLPG2737 Add-on Increases Effectiveness of Orkambi for Cystic Fibrosis, Phase 2 Results Show appeared first on Cystic Fibrosis News Today. | ||
|
No hay comentarios:
Publicar un comentario